COMPARATIVE MORPHOLOGICAL AND MORPHOMETRIC CHARACTERISTICS OF THE LIVER MICROCIRCULATORY BED IN RATS UNDER LONGTERM USE OF CANNABIDIOL OIL AND HEMP SEED OIL

Authors:

Abstract:

The study investigates the effect of long-term administration of cannabidiol oil and hemp seed oil on the state of the microcirculatory bed of the rat liver. The experiment was conducted on 80 male rats that received a cannabidiol oil and hemp seed oil as dietary supplements for 8 and 10 weeks. The article presents a comparative morphological characteristic with a morphometric assessment of the microcirculatory bed of the rat liver. The structural organization of the vascular compartment of the rat liver under long-term exposure to cannabidiol oil and hemp oil did not undergo dystrophic and necrotic changes. A significantly higher average diameter of interlobular veins and sinusoids was established in the cannabidiol oil experimental group compared to the hemp oil group (p <0.0001) and the control group (p <0.0001). The average diameters of the interlobular artery in the experimental groups of cannabidiol oil and hemp oil in the two series of the experiment did not differ significantly from each other (p>0.05). Dilatation of sinusoids and slight hyperemia of single central veins in the cannabidiol oil group in both series did not indicate impaired blood outflow from the hepatic lobule, morphological changes were mainly adaptive nature. Thus, the experimental administration of cannabidiol oil and hemp seed oil indicates the safety of use for 8 and 10 weeks.

Keywords:

liver rats vessels histology morphometry cannabidiol oil hemp seed oil safety

References:

1. Cassano T, Villani R, Pace L, Carbone A, Bukke VN, Orkisz S. et al. From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases. Front Pharmacol. 2020 Mar 6; 11:124. https://doi.org/10.3389/fphar.2020.00124
2. Chen S, Kim J-K. The Role of Cannabidiol in Liver Disease: A Systemic Review. International Journal of Molecular Sciences. 2024; 25(4):2370. https://doi.org/10.3390/ijms25042370
3. Crescente G, Piccolella S, Esposito A, Scognamiglio M, Fiorentino A, Pacifico S. Chemical composition and nutraceutical properties of hempseed: an ancient food with actual functional value. Phytochem Rev. 2018; 17:733–49. https://doi.org/10.1007/s11101-018-9556-2
4. Devi V, Khanam S. Comparative study of different extraction processes for hemp (Cannabis sativa) seed oil considering physical, chemical and industrial-scale economic aspects. J. Clean. Prod. 2019; 207:645–57. https://doi.org/10.1016/j.jclepro.2018.10.036
5. Ewing LE, Skinner CM, Quick CM, Kennon-McGill S, McGill MR, Walker LA. et al. Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model. Molecules. 2019 Apr 30;24(9):1694. https://doi.org/10.3390/molecules24091694
6. Gong M, Lu H, Li L, Feng M, Zou Z. Integration of transcriptomics and metabonomics revealed the protective effects of hemp seed oil against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis in mice. Food Funct. 2023; 14:2096–2111. https://doi.org/10.1039/d2fo03054c
7. Greenwich Biosciences. Epidiolex [Package Insert]; Greenwich Biosciences: Carlsbad, CA, USA, 2018.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf
8. Harrison J. VanDolah, Brent A. Bauer, Karen F. Mauck. Clinicians’ Guide to Cannabidiol and Hemp Oils. Mayo Clin Proc. 2019: 1-12. https://doi.org/10.1016/j.mayocp.2019.01.003
9. Majewski M, Jurgoński A. The Effect of Hemp (Cannabis sativa L.) Seeds and Hemp Seed Oil on Vascular Dysfunction in Obese Male Zucker Rats. Nutrients. 2021; 13(8):2575. https://doi.org/10.3390/nu13082575
10. Mcgrath S, Bartner LR, Rao S, Kogan LR, Hellyer P. Report of adverse effects associated with the administration of cannabidiol in healthy dogs. Journal of the American Holistic Veterinary Medical Association. 2018; 52: 34–9.https://holistic-tails.com/wp-content/uploads/2020/05/AHVMA-2018-V52-CannabisAdverseEffects.pdf
11. McPartland JM, Guy GW, Hegman W. Cannabis is indigenous to Europe and cultivation began during the Copper or Bronze age: A probabilistic synthesis of fossil pollen studies.Vegetation History and Archaeobotany. 2018; 27(4): 635-48. https://doi.org/10.1007/s00334-018-0678-7
12. Muscarà C, Smeriglio A, Trombetta D, Mandalari G, La Camera E, Grassi G. et al. Phytochemical characterization and biological properties of two standardized extracts from a non-psychotropic Cannabis sativa L. cannabidiol (CBD)-chemotype. Phytother Res. 2021 Sep; 35(9):5269-81. https://doi.org/10.1002/ptr.7201
13. Nataly Martini. Hempseed oil. Journal of Primary Health Care. 2021; 13(4): 375-376. https://doi.org/10.1071/HC19567
14. Occhiuto C, Aliberto G, Ingegneri M, Trombetta D, Circosta C, Smeriglio A. Comparative Evaluation of the Nutrients, Phytochemicals, and Antioxidant Activity of Two Hempseed Oils and Their Byproducts after Cold Pressing. Molecules. 2022; 27(11):3431. https://doi.org/10.3390/molecules27113431
15. Pavlovic R, Nenna G, Calvi L, Panseri S, Borgonovo G, Giupponi L. et al. Quality Traits of "Cannabidiol Oil": Cannabinoids Content, Terpene Fingerprint and Oxidation Stability of European Commercially Available Preparations. Molecules. 2018 May 20; 23 (5): 1230. https://doi.org/10.3390/molecules23051230
16. R C Coelho MP, de O P Leme F, A Moreira F, E M T Branco S, M Melo M, G de Melo E. Current review of hemp-based medicines in dogs. J Vet PharmacolTher. 2021. 44(6): 870-82. https://doi.org/10.1111/jvp.13016
17. Schlag AK, O'Sullivan SE, Zafar RR, Nutt DJ. Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics. Neuropharmacology. 2021; 191: 108586. https://doi.org/10.1016/j.neuropharm.2021.108586
18. Suvarna SK, Layton C, Bancroft GD. (Eds.). Bancroft's Theory and Practice of Histological Techniques, 8th Edition. Elsevier; 2019. 558p.https://doi.org/10.1016/B978-0-7020-6864-5.00008-6
19. Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C. et al.; GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Mar 17;391(10125):1085–96. https://doi.org/10.1016/S0140-6736(18)30136-3

Publication:

«World of Medicine and Biology» Vol. 22 No. 96 (2026) , с. 181-187
УДК 616.36:611.161]-005–018: [615.34:582.635.38]-019–092.9

DOI:

https://doi.org/10.26724/2079-8334-2026-2-96-181-187